FibroGen (NASDAQ:FGEN) Now Covered by StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of FibroGen in a research report on Tuesday, March 18th. William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Tuesday, April 1st.

FibroGen Stock Down 2.5 %

Shares of FGEN stock opened at $0.27 on Monday. The firm has a market cap of $27.56 million, a price-to-earnings ratio of -0.22 and a beta of 0.87. FibroGen has a 12 month low of $0.18 and a 12 month high of $1.74. The stock has a 50-day moving average price of $0.43 and a 200 day moving average price of $0.42.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million. Sell-side analysts predict that FibroGen will post -0.8 earnings per share for the current fiscal year.

Insider Buying and Selling at FibroGen

In other FibroGen news, Director James A. Schoeneck bought 250,000 shares of FibroGen stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of $0.35 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the director now owns 323,722 shares in the company, valued at approximately $113,302.70. The trade was a 339.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Thane Wettig bought 145,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was acquired at an average cost of $0.35 per share, with a total value of $50,750.00. Following the completion of the purchase, the chief executive officer now owns 543,329 shares of the company’s stock, valued at approximately $190,165.15. This trade represents a 36.40 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.98% of the company’s stock.

Institutional Trading of FibroGen

A number of large investors have recently bought and sold shares of FGEN. FMR LLC boosted its holdings in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 68,569 shares during the period. Geode Capital Management LLC lifted its position in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. lifted its position in FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 1,358,194 shares in the last quarter. Franklin Street Advisors Inc. NC boosted its stake in FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 100,000 shares during the period. Finally, Renaissance Technologies LLC increased its holdings in FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 605,572 shares in the last quarter. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.